Predictors of euthyreosis in hyperthyroid patients treated with radioiodine
Adult
Age Factors
Aged
Aged, 80 and over
Female
Goiter, Nodular
/ blood
Graves Disease
/ blood
Humans
Hyperthyroidism
/ blood
Iodine Radioisotopes
/ therapeutic use
Logistic Models
Male
Middle Aged
Multivariate Analysis
Organ Size
Radionuclide Imaging
Retrospective Studies
Thyroid Gland
/ diagnostic imaging
Thyrotropin
/ blood
Thyroxine
/ blood
Treatment Outcome
Triiodothyronine
/ blood
131I−
Euthyreosis
Factors
Graves’ disease
Hyperthyroidism
Predictors
Radioiodine
Toxic multinodular goiter
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
01 Jun 2020
01 Jun 2020
Historique:
received:
18
07
2019
accepted:
10
05
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
2
4
2021
Statut:
epublish
Résumé
Radioiodine (RAI) treatment for hyperthyroidism is a very common modality, chosen by physicians worldwide. The outcome of the therapy, however, is not always predictable. While rendering a patient hypo- or euthyroid is meant as a therapeutic success, the latter does not require lifelong hormonal supplementation. The aim of our study is to determine predictors of euthyreosis in patients who underwent RAI treatment. Medical records of 144 patients who had undergone RAI therapy were examined. Laboratory and clinical data were analyzed statistically. Ultrasonography findings, such as thyroid volume, nodules' size and characteristics had been collected at the beginning of treatment and 6 months after the administration of radioiodine The analysis showed that age (OR 1,06; 95%CI 1.025-1.096, p = 0,001), thyroid gland volume (OR 1,04; 95%CI 1,02-1,06; p < 0.001) and iodine uptake level (OR 0,952; 95%CI 0,91-0,98; p = 0,004) were significant factors of achieving normal thyroid function after RAI therapy. According to multivariate logistic regression analysis, in GD patients only age has been shown to be a significant factor (OR 1,06; 95%CI 1,001-1,13; p = 0.047), while in TMNG patients' age (OR 1,04; 95%CI 1-1,09; p = 0.048), thyroid gland volume (OR 1.038; 95%CI 1.009-1.068; p = 0.009) and iodine uptake level (OR 0.95; 95%CI 0.9-0.99; p = 0.02) all have been proven to be significant predictors of achieving euthyroidism. The more advanced age, larger volume of thyroid gland and lower iodine uptake level are predictors of euthyreosis after RAI treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Radioiodine (RAI) treatment for hyperthyroidism is a very common modality, chosen by physicians worldwide. The outcome of the therapy, however, is not always predictable. While rendering a patient hypo- or euthyroid is meant as a therapeutic success, the latter does not require lifelong hormonal supplementation. The aim of our study is to determine predictors of euthyreosis in patients who underwent RAI treatment.
METHODS
METHODS
Medical records of 144 patients who had undergone RAI therapy were examined. Laboratory and clinical data were analyzed statistically. Ultrasonography findings, such as thyroid volume, nodules' size and characteristics had been collected at the beginning of treatment and 6 months after the administration of radioiodine
RESULTS
RESULTS
The analysis showed that age (OR 1,06; 95%CI 1.025-1.096, p = 0,001), thyroid gland volume (OR 1,04; 95%CI 1,02-1,06; p < 0.001) and iodine uptake level (OR 0,952; 95%CI 0,91-0,98; p = 0,004) were significant factors of achieving normal thyroid function after RAI therapy. According to multivariate logistic regression analysis, in GD patients only age has been shown to be a significant factor (OR 1,06; 95%CI 1,001-1,13; p = 0.047), while in TMNG patients' age (OR 1,04; 95%CI 1-1,09; p = 0.048), thyroid gland volume (OR 1.038; 95%CI 1.009-1.068; p = 0.009) and iodine uptake level (OR 0.95; 95%CI 0.9-0.99; p = 0.02) all have been proven to be significant predictors of achieving euthyroidism.
CONCLUSIONS
CONCLUSIONS
The more advanced age, larger volume of thyroid gland and lower iodine uptake level are predictors of euthyreosis after RAI treatment.
Identifiants
pubmed: 32487052
doi: 10.1186/s12902-020-00551-2
pii: 10.1186/s12902-020-00551-2
pmc: PMC7268615
doi:
Substances chimiques
Iodine Radioisotopes
0
Iodine-131
0
Triiodothyronine
06LU7C9H1V
Thyrotropin
9002-71-5
Thyroxine
Q51BO43MG4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
77Références
Nucl Med Commun. 2010 Mar;31(3):201-5
pubmed: 19907353
Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1118-24
pubmed: 12192554
Ann Pediatr Endocrinol Metab. 2014 Sep;19(3):122-6
pubmed: 25346915
Clin Physiol Funct Imaging. 2006 May;26(3):167-70
pubmed: 16640512
Nuklearmedizin. 2008;47(1):13-7
pubmed: 18278207
Ulster Med J. 1980;49(1):71-8
pubmed: 7394928
Br J Radiol. 2016 Aug;89(1064):20160418
pubmed: 27266544
Thyroid. 1991;1(2):129-35
pubmed: 1688014
Int J Endocrinol. 2016;2016:7863867
pubmed: 27446210
Clin Endocrinol (Oxf). 1995 Sep;43(3):325-9
pubmed: 7586602
Dan Med Bull. 1991 Feb;38(1):87-9
pubmed: 1878025
J Clin Endocrinol Metab. 2012 Dec;97(12):4549-58
pubmed: 23043191
Endocr J. 2004 Apr;51(2):127-32
pubmed: 15118261
Eur J Nucl Med. 2001 Oct;28(10):1489-95
pubmed: 11685491
J Clin Endocrinol Metab. 2001 Aug;86(8):3611-7
pubmed: 11502786
Ulster Med J. 2013 May;82(2):85-8
pubmed: 24082285
Eur J Endocrinol. 2005 Jul;153(1):15-21
pubmed: 15994741
Clin Endocrinol (Oxf). 2009 Jan;70(1):129-38
pubmed: 18462261
Nuklearmedizin. 1997 Apr;36(3):81-6
pubmed: 9162906
J Clin Endocrinol Metab. 2003 Mar;88(3):978-83
pubmed: 12629071
J Clin Endocrinol Metab. 2000 Mar;85(3):1038-42
pubmed: 10720036
Clin Endocrinol (Oxf). 2004 Nov;61(5):641-8
pubmed: 15521969
Endocrine. 2004 Oct;25(1):55-60
pubmed: 15545707
J Clin Endocrinol Metab. 1999 Apr;84(4):1229-33
pubmed: 10199759
Arch Med Sci. 2010 Aug 30;6(4):611-6
pubmed: 22371808
Eur J Nucl Med Mol Imaging. 2003 Apr;30(4):525-31
pubmed: 12541136
Thyroid. 1997 Apr;7(2):247-51
pubmed: 9133695
Ann Surg Oncol. 2014 Dec;21(13):4174-80
pubmed: 25001092
Eur J Endocrinol. 1999 Aug;141(2):117-21
pubmed: 10427153
Clin Endocrinol (Oxf). 2007 Jun;66(6):757-64
pubmed: 17466000
Eur J Clin Invest. 2004 May;34(5):365-70
pubmed: 15147334
Endocr Rev. 2012 Dec;33(6):920-80
pubmed: 22961916
J Clin Endocrinol Metab. 2007 Sep;92(9):3547-52
pubmed: 17609305
Am J Med Sci. 2014 Oct;348(4):288-93
pubmed: 24805788
Eur J Nucl Med Mol Imaging. 2006 Jun;33(6):730-7
pubmed: 16607544
Indian J Nucl Med. 2015 Oct-Dec;30(4):309-13
pubmed: 26430313
JAMA. 1995 Mar 8;273(10):808-12
pubmed: 7532241
Br Med Bull. 2011;99:39-51
pubmed: 21893493
Arch Intern Med. 1999 Jun 28;159(12):1364-8
pubmed: 10386513
J Clin Endocrinol Metab. 1998 Jan;83(1):40-6
pubmed: 9435414
Clin Endocrinol (Oxf). 2005 Mar;62(3):331-5
pubmed: 15730415
Thyroid. 2016 Oct;26(10):1343-1421
pubmed: 27521067
Eur J Clin Invest. 1995 Mar;25(3):186-93
pubmed: 7781666
World J Nucl Med. 2013 May;12(2):57-60
pubmed: 25125996
J Clin Endocrinol Metab. 2002 Mar;87(3):1073-7
pubmed: 11889166